Spleen News and Research

RSS

Scientists discover how liver destroys immune T-cells

Scientists at the Centenary Institute in Sydney have seen for the first time (in mice) how the liver goes independent, engulfing and destroying the body's defence troops-T-cells.

20 Sep 2011

New insight into how nervous system regulates immunity

Scientists have identified a surprising new role for a new type of T cell in the immune system: some of them can be activated by nerves to make a neurotransmitter (acetylcholine) that blocks inflammation. The discovery of these T cells is novel and suggests that it may be possible to treat inflammation and autoimmune diseases by targeting the nerves and the T cells. The study was published this week in Science.

17 Sep 2011

Memphis operation successfully separates twins joined at the spine

Joshua and Jacob Spates, all of seven months old spent their initial months outside the womb as conjoined twins. Now they are recovering in the pediatric intensive care unit of a Memphis hospital after a successful 13-hour surgery to separate them.

15 Sep 2011

Researchers discover protein signals responsible for preserving anti-viral antibodies

Our immune system is capable of a remarkable feat: the ability to remember infections for years, even decades, after they have first been encountered and defeated. While the antibodies we make last only about a month, we retain the means of making them for a lifetime.

3 Sep 2011

CD8 alpha+ dendritic cells can help the body beat back infection

The same trait that makes a rare immune cell invaluable in fighting some infections also can be exploited by other diseases to cause harm, two new studies show.

29 Aug 2011

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

The U.S. Food and Drug Administration today approved Adcetris to treat Hodgkin lymphoma and a rare lymphoma known as systemic anaplastic large cell lymphoma.

20 Aug 2011

Researchers discover novel combination of two mutations in a patient with ADHD

Often enough, in science as in life, unexpected knowledge has a personal impact. Researchers seeking rare gene variants in just a few individuals with attention-deficit hyperactivity disorder (ADHD) discovered that one patient had a novel combination of two mutations.

21 Jul 2011

Chaos in biochemical alterations of cancer cells

Using the latest gene sequencing tools to examine so-called epigenetic influences on the DNA makeup of colon cancer, a Johns Hopkins team says its results suggest cancer treatment might eventually be more tolerable and successful if therapies could focus on helping cancer cells get back to normal in addition to strategies for killing them.

27 Jun 2011

FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, announced today that their lead program, SBC-102, an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, currently in clinical trials, has been granted fast track designation by the U.S. Food and Drug Administration (FDA).

23 Jun 2011

New genetic research holds promise for patients with Chuvash polycythemia

New research conducted at UNC Lineberger Comprehensive Cancer Center, offers hope for people with a rare disorder called Chuvash polycythemia.

23 Jun 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

Trimeris, Synageva enter definitive merger agreement

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, and Trimeris, Inc., announced today that they have entered into a definitive agreement under which Synageva will merge with Trimeris in an all-stock transaction.

13 Jun 2011

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Incyte Corporation announced today additional symptom improvement and quality of life (QoL) results from COMFORT-I, a randomized, double-blinded, placebo-controlled Phase III trial of Incyte's JAK1 and JAK2 inhibitor, ruxolitinib, in patients with myelofibrosis (MF).

13 Jun 2011

Lethal malaria parasite has biochemical weakness

Every year, 10,000 pregnant women and up to 200,000 newborn babies are killed by the malaria parasite. Doctors all around the globe have for years been looking in vain for a medical protection, and now researchers from the University of Copenhagen have found the biochemically weakness of the lethal malaria parasite, and will now start developing a vaccine to combat pregnancy related malaria.

8 Jun 2011

Specific forms of lymphoma create their own survival niche

Cancer cells do not grow equally well everywhere in the body. Often, they first create the conditions in which they can grow. Many years ago researchers discovered that solid tumors attract blood vessels to ensure their supply of nutrients by secreting specific factors.

7 Jun 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Incyte Corporation announced today results from the global, pivotal Phase III clinical program of ruxolitinib in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.

6 Jun 2011

Battelle, Perma-Fix sign exclusive option agreement to make medical isotopes

Perma-Fix Environmental Services, Inc. today announced it has signed an exclusive option agreement with Battelle, which operates Pacific Northwest National Laboratory for the U.S. Department of Energy, to license technology from PNNL for use with Perma-Fix's proprietary process to safely and cost-effectively produce Molybdenum-99 (Mo-99), which is used to make Technetium 99m (Tc-99m).

4 Jun 2011

Green tea consumption increases number of 'regulatory T cells', prevents autoimmune disease

One of the beneficial compounds found in green tea has a powerful ability to increase the number of "regulatory T cells" that play a key role in immune function and suppression of autoimmune disease, according to new research in the Linus Pauling Institute at Oregon State University.

3 Jun 2011

Removal of tonsils and appendix heightens risk of heart attack: Study

According to a new study surgical removal of tonsils and the appendix before the age of 20 is likely to elevate the risk of a premature heart attack. The researchers found that tonsillectomy (removal of tonsils) increased the risk by 44 per cent and removal of the appendix by 33 per cent. The risk increases were even higher when both the tonsils and appendix were removed.

2 Jun 2011

Appendix and tonsil surgeries before age 20 can increase risk of premature heart attack

The surgical removal of the appendix and tonsils before the age of 20 was associated with an increased risk of premature heart attack in a large population study performed in Sweden. Tonsillectomy increased the risk by 44% (hazard ratio 1.44) and appendectomy by 33% (HR 1.33).

1 Jun 2011

Spleen News and Research

Scientists discover how liver destroys immune T-cells

New insight into how nervous system regulates immunity

Memphis operation successfully separates twins joined at the spine

Researchers discover protein signals responsible for preserving anti-viral antibodies

CD8 alpha+ dendritic cells can help the body beat back infection

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

Researchers discover novel combination of two mutations in a patient with ADHD

Chaos in biochemical alterations of cancer cells

FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency

New genetic research holds promise for patients with Chuvash polycythemia

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

Trimeris, Synageva enter definitive merger agreement

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Lethal malaria parasite has biochemical weakness

Specific forms of lymphoma create their own survival niche

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Battelle, Perma-Fix sign exclusive option agreement to make medical isotopes

Green tea consumption increases number of 'regulatory T cells', prevents autoimmune disease

Removal of tonsils and appendix heightens risk of heart attack: Study

Appendix and tonsil surgeries before age 20 can increase risk of premature heart attack

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News